FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.
Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...
The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...
Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...
Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...
Phase Inpatient Withdrawal Programme for Long-Term Opioid Use in Non-Cancer Pain,” published in the March 2025 issue of ...
Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...
"We need to pass legislation that ensures patients have better access to FDA-approved, non-opioid pain management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results